Table 1. Patient characteristics.

	IT+PT					PT
Cohort	16 mg	32 mg	48 mg	64 mg	96 mg	96 mg	Total
No. of patients, n	3	3	3	3	5	6	23
Age, years
Median	71	67	81	69	73	69	72
Range	49–71	66–76	79–85	69–80	69–77	40–85	40–85
Sex, n (%)
Male	2 (67)	0 (0)	0 (0)	1 (33)	4 (80)	4 (67)	11 (48)
Female	1 (33)	3 (100)	3 (100)	2 (67)	1 (20)	2 (33)	12 (52)
ECOG performance status, n (%)
0	2 (67)	3 (100)		3 (100)	4 (80)	5 (83)	17 (74)
1	1 (33)		3 (100)		1 (20)	1 (17)	6 (26)
Time from diagnosis, years
Median	3.7	8.4	1.5	1.8	1.7	1.2	1.7
Range	0.8–9.8	3.0–9.8	1.0–3.7	0.8–18.4	0.7–6.8	0.3–2.0	0.3–18.4
Prior treatment, n (%)
Surgery	3 (100)	3 (100)	3 (100)	3 (100)	6 (80)	6 (100)	23 (100)
Immunotherapy	1 (33)	1 (33)		1 (33)	1 (20)	1 (17)	5 (22)
Radiotherapy			1 (33)		1 (33)		2 (9)
Chemotherapy	1 (33)	1 (33)			1 (20)		3 (13)
Melanoma stage at inclusion, n (%)
III	2 (67)	3 (100)	2 (67)	2 (67)	3 (60)	6 (67)	16 (70)
IV	1 (33)		1 (33)	1 (33)	2 (40)	2 (33)	7 (30)
Site of metastases, n (%)
Leg	3 (100)	3 (100)	3 (100)	3 (100)	2 (40)	3 (50)	17 (74)
Arm					1 (27)		1 (4)
Chest						1 (17)	1 (4)
Head					2 (40)	2 (33)	4 (17)
Size of the tumour lesions, mm
Injected with DT01
Median	16	8	24	11	10	6	9
Range	3–36	5–25	9–33	4–17	8–25	3–30	3–36
Non-injected with DT01
Median	2	4.5	7	8	7	4	6
Range	2–15	4–6	6–20	4–20	4–17	2–10	2–20
All
Median	5	6	12	9	8	5	7
Range	2–36	4–25	6–33	4–20	4–25	2–30	2–36
No. of treated lesions, n
Injected with DT01	6	5	6	6	10	12	45
Non-injected with DT01	5	4	5	7	13	6	40
Total	11	9	11	13	23	18	85

Abbreviations: AJCC=American Joint Committee on Cancer; ECOG=Eastern Cooperative Oncology Group; IT=intratumoural; PT=peritumoural.

AJCC classification was used for melanoma staging.